Mr. Chairman, I have another point of order. I'm sorry to do this again, and I was hesitant to raise a point of order at the question, but I should have.
The witness is getting into the issue of paid plasma, which is a very important issue but has absolutely nothing to do with the study before this committee.
If I were to ask questions, I would have 20 questions to ask this witness on the safety and efficacy of paid plasma, but obviously I won't have the opportunity to do so because he's been called here today not to testify on that issue but to talk about his experience with bulk buying in a national pharmacare plan.
I'm going to ask that the witness not continue on in this regard. If he wants to come back and if this committee wants to study the safety and risk issues of paid plasma products in this country, I'm certainly willing to do that, but that is far beyond the scope of the study before us.